Biosynthesis: Making the Impossible Possible in Medicinal Cannabis
NetworkNewsWire Editorial Coverage: The U.S. pharmaceutical industry is pocked with pitfalls that make it difficult for the development of cannabis-based drugs. To receive FDA approval, drug manufacturers must produce a consistent, pharmaceutical-grade product. Drug researchers with cannabis-based candidates are largely dependent on cannabis producers to access their drug raw materials. And therein lies the issue. The cannabis production sector has had its share of product recalls, and is saddled with pricey cost of commercial cultivation. The roadblocks are considerable - from legal and execution standpoints - making these efforts not quite impossible but certainly, currently, difficult. Canada-based biopharmaceutical company InMed…







